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The Evolution From Surgery to
Percutaneous Mitral Valve Interventions
The Role of the Edge-to-Edge Technique
Francesco Maisano, MD, Giovanni La Canna, MD, Antonio Colombo, MD, Ottavio Alfieri, MD
Milano, Italy
The edge-to-edge technique is a versatile procedure for mitral valve repair. Its technical simplicity has been the
prerequisite for the development of a number of transcatheter technologies to perform percutaneous mitral
valve repair. The evolution from a standard open heart surgical to percutaneous procedure involved the applica-
tion of the technique in minimally invasive robotic surgery and direct access (transatrial) off-pump suture-based
repair and finally in the fully percutaneous approach with either suture-based or device (clip)-based approach.
The MitraClip (Abbott Vascular, Menlo Park, California) is currently available for clinical use in Europe, and it is
mainly applied to treat high-risk patients with functional mitral regurgitation. A critical review of the surgical as
well as the early percutaneous repair data is necessary to elucidate the clinical role and the potential for future
developments of the edge-to-edge repair in the treatment of mitral regurgitation. (J Am Coll Cardiol 2011;58:
2174–82) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.046The edge-to-edge is a surgical technique developed by Alfieri
(1–3) in the early 1990s to treat mitral regurgitation (MR).
The technique is technically simple and used to treat both
organic and functional MR. The surgical technique consists of
the suture of the free edge of the leaflets at the site of
regurgitation, creating a valve with 2 orifices when the regur-
gitation originates from the middle scallops. For this reason it
has also been named “double orifice” technique (Fig. 1).
As opposed to conventional techniques, the edge-to-edge
repair is not directly addressing the anatomical lesion: MR
is corrected by obliteration of the regurgitant orifice at the
leaflet level. This innovative concept implies that the same
technique can be applied to different anatomical and func-
tional conditions.
The value of the technique has been long debated in the
surgical arena, initially with several detractors and few
adopters, mainly because of the perceived non-physiological
consequences. Yet, the technique has been demonstrated
safe, effective, and durable, and many surgeons have pro-
gressively adopted it.
Its technical simplicity and versatility has been the foun-
dation for the development of transcatheter technologies,
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accepted July 12, 2011.including the MitraClip (Abbott Vascular, Inc., Menlo
Park, California). Herein we review the evidence on the
surgical as well as the transcatheter techniques outcomes to
better understand the clinical role of percutaneous mitral
valve interventions.
The Origins
The edge-to-edge technique was first performed in 1991 to
successfully treat a patient with anterior leaflet prolapse. At
that time, anterior leaflet repair was considered challenging,
and most patients would undergo replacement. The day
before, Alfieri had operated on another patient for correc-
tion of atrial septal defect who had, as a concomitant
asymptomatic condition, a perfectly competent congenital
double-orifice valve. Initially the technique was applied only
selectively, in patients with complex anatomies, and usually
without a concomitant annuloplasty, because of the fear of
stenosis. Because mid-term results were suggesting safety,
effectiveness, and durability, gradually the edge-to-edge tech-
nique became routine at our institution. At the peak of the
adoption rate (between 1998 and 2005), it was used in
one-third of patients undergoing mitral valve repair. The most
common indications were anterior/bileaflet disease and func-
tional MR. More recently, the rate of edge-to-edge repair at
our institution decreased in favor of more anatomical correc-
tions, although it remains used in approximately 15% of
patients with complex anatomy or requiring an expedited
procedure.
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Numerous experimental models addressed the hemody-
namic and structural effects of the technique (4,5).
The first concern was the risk of creating stenosis,
although this was rarely seen in clinical practice. A compu-
tational model (Fig. 2) of the double orifice mitral valve
with orifices of same or different size suggested hemody-
namics are not affected by the double orifice configuration,
even in case of asymmetric position of the double orifice
suture (6).
Later, clinical studies (7) showed that the procedure does
not impair valve diastolic function either at rest or under
exercise. Agricola et al. (8) reported normal response to
exercise echocardiography: at peak stress, heart rate, systolic
blood pressure, and stroke volume were significantly in-
creased, maintaining a physiological behavior of the valve.
Valve reserve was preserved: planimetric area increased
significantly (3.2 0.6 cm2 vs. 4.3 0.7 cm2, p 0.00001)
uring exercise. Subsequently, Hori et al. (7) observed that
xercise response of patients treated with edge-to-edge
epair is equal to those treated with conventional repairs.
Limited durability and the risk of suture dehiscence were
nitially perceived as a critical issue, although rarely seen in
Figure 1 Surgical Edge-to-Edge Technique Versus MitraClip
(A) The surgical technique involves a continuous suture of the free edge of the le
orifice valve is created. (B) The sutures engage the free edge of the facing leaflet
degenerative disease, and minimal in case of functional mitral regurgitation). (C)
similarly to the surgical technique. The drawing illustrates the clip partially open, t
firmed, the clip is closed to enhance coaptation. (D) The free edges of the leaflets
facing. Compared with surgery where tissue is imbricated into the suture with no e
apposition of leaflets to enhance coaptation. Figure illustration by Craig Skaggs.linical practice. Nielsen et al. (4)
nalyzed the tension forces act-
ng on the edge-to-edge suture in
n ovine model of acute ischemic
R. They observed cyclic changes
n the forces, proportional to the
eptolateral annular dimension.
hese results were confirmed by
otta et al. (5) with a 3-dimensional (3D) computational
odel. The surgical edge-to-edge has been usually associ-
ted with annuloplasty, on the basis of these findings.
urgical Technique:
hat to Do and What Should Not Be Done
he edge-to-edge technique has evolved in a standardized
pproach, on the basis of clinical experience and laboratory
ndings (5,6), with improvement of efficacy and durability
2). To be effective, the edge-to-edge suture should incor-
orate the diseased segment(s) completely. Although a long
uture reduces structural stress on the leaflets (5), it deter-
ines a larger reduction of effective orifice area. A middle
uture creates a 40% to 50% reduction of valve area from
aseline. This is usually not an issue in degenerative disease,
Abbreviations
and Acronyms
3D  3-dimensional
MR  mitral regurgitation
TEE  transesophageal
echocardiography
t the site of the regurgitation. In case the lesion is in the A2-P2 area, a double
re bite depth depends on the amount of redundant tissue (larger in case of
traClip (Abbott Vascular, Menlo Park, California) is implanted in the A2-P2 region,
onstrate tissue penetration into the clip. Once proper leaflet grasping is con-
ngaged between the clip arms and the grippers. The clip is closed with leaflet
e of planar surface of coaptation, the MitraClip is designed to induce a linearaflets a
s, sutu
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From Surgery to Percutaneous Edge-to-Edge November 15, 2011:2174–82but it might cause mitral stenosis in patients with valve
area smaller than 4 cm2. An eccentric position of the
dge-to-edge suture determines smaller reduction of
alve area. Additionally, post-repair effective orifice area
epends on leaflet mobility and pliability; therefore the
echnique is less applicable and associated with shorter
urability in case of rheumatic disease (1). Suture should
e symmetric to avoid distortions and increased stress.
riginally, the edge-to-edge sutures were reinforced with
ledgets; with increasing experience, continuous sutures
ave been used more often.
linical Outcomes in Diverse Clinical Settings
n 1998, we reported the first relatively large series of
atients treated with the edge-to-edge technique (3), in-
luding 121 patients (of 432 valve repairs) operated between
991 and 1997. Most patients had degenerative disease with
nterior or bileaflet disease. A double orifice repair was done
n 60% of patients. Annuloplasty was performed in only 7%
f patients (small mitral annulus in 6 patients, and rheu-
atic disease in 2 patients). Excluding annuloplasty, the
dge-to-edge was used as an isolated technique in 73% of
ases, even for multiple lesions. Hospital mortality was
.6%, and 6-year actuarial survival was 92 3.1%. Freedom
rom reoperation was 95  4.8% overall and 98  1.6% for
atients with isolated anterior leaflet prolapse; no patient
ith posterior prolapse required reintervention. Echocar-
Figure 2 Mathematical Model of the Hemodynamics After the
The mathematical model has been developed to simulate the diastolic flow patter
orifice (A), a double orifice with equal orifice sizes (B), and 1 with uneven orifice s
valves, suggesting that the hemodynamics of the mitral valve are not influenced biographic follow-up showed a mean degree of MR of (.4  0.83 with 91% of patients having no or trivial MR.
ean valve area was 3.0  1 cm2, with no patients with
itral stenosis.
Subsequently, we published a homogeneous series of 82
atients (2) treated with edge-to-edge technique as a
tandardized approach to correct Barlow’s disease with
ileaflet prolapse (condition considered a contraindication
or repair). Annuloplasty was performed in 75 patients.
Today anterior/bileaflet prolapse is effectively treated
ith neochordae implantation; nevertheless the edge-to-
dge technique has been the first method to neutralize
nterior leaflet lesions as risk factor for repair failure and
horter durability (9,10). De Bonis et al. (11) compared the
ong-term outcomes of 122 patients with anterior prolapse
reated by edge-to-edge repair with 605 patients with
osterior prolapse treated with resection. All patients had
oncomitant annuloplasty. Hospital mortality was 0% and
.3% in the edge-to-edge and resection groups, respectively.
t 10 years, overall survival was 91  4% for edge-to-edge
nd 93  2% for resection group (p  0.18). Freedom from
eoperation was 96  2% and 96  1% (p  0.37) in the
dge-to-edge and resection groups, respectively. Echocar-
iographic follow-up showed comparable freedom from
ecurrent MR for the 2 techniques.
Other groups reported their experience with the edge-to-
dge technique in the setting of degenerative disease,
onfirming the aforementioned results (12,13), including
hen used with minimally invasive or robotic approach
le Orifice Edge-to-Edge Repair
mitral valves of the same area but with 3 anatomical configurations: a single
C). Flow velocity patterns show similar velocities in single and in double orifice
eometrical conformation of the orifice.Doub
ns of 3
izes (
y the g14,15).
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November 15, 2011:2174–82 From Surgery to Percutaneous Edge-to-EdgeThe Alfieri technique has been effectively used to treat
functional MR, usually as an adjunct to undersized annu-
loplasty (3,13,16). We selectively applied it with an echo-
based approach in patients with coaptation depth longer
than 10 mm. In a retrospective series (16) of 77 patients
with functional MR treated with annuloplasty alone (n  23)
or in association with edge-to-edge (n  54), freedom from
repair failure at 1.5 years was 95  3% and 77  12%,
espectively (p  0.04), and the multivariable analysis
dentified the absence of the edge-to-edge suture as an
ndependent factor for repair failure.
The edge-to-edge repair has been successfully used in
ther settings: to treat failed repair as a bailout procedure, to
orrect systolic anterior motion in the context of hypertro-
hic cardiomyopathy and to treat secondary MR in patients
ndergoing ventricular remodeling or aortic valve surgery.
e initially applied it in rheumatic disease patients, but we
bserved poor long-term outcomes and greater risk of high
ransvalvular gradients (1).
dge-to-Edge Without Annuloplasty
nnuloplasty is routinely performed in surgical mitral repair
o improve early and long-term results (9). The same
oncept applies to the edge-to-edge technique: in the overall
opulation, the absence of the annuloplasty is associated
ith shorter durability (1). Although initially we often
mitted annuloplasty in the fear of inducing stenosis,
ubsequently a ring has been routinely implanted in most
atients. Alfieri et al. (1) reported shorter durability in
atients treated without annuloplasty. However, these pa-
ients usually had conditions preventing ring implantation
hat could directly influence durability such as annular
alcification, endocarditic or rheumatic disease, setting of
inimally invasive and robotic interventions, or a previously
ailed attempt of repair. The outcomes of 81 patients treated
y edge-to-edge repair without annuloplasty showed overall
5  7% survival and 89  3.9% freedom from reoperation
t 4 years. Annular calcification was associated with higher
eoperation rate (77 22% vs. 95 4.6% in the calcified vs.
oncalcified annulus, p  0.03). Late failure was predicted
y early residual MR assessed either by saline testing or
ntraoperative transesophageal echocardiography (TEE)
17). Therefore, in absence of annular calcification or
omplex anatomy (rheumatic disease, endocarditis, rescue
epair, and the like), mid-term durability of isolated edge-
o-edge is acceptable, as confirmed by a sub-analysis of the
ong-term outcomes of selected patients with ideal anatomy
reated without annuloplasty (18). Although these findings
ere the clinical proof of concept for the isolated percuta-
eous treatment, we strongly believe that the addition of a
ercutaneous annuloplasty would improve clinical results
nd expand the indications for transcatheter mitral valve
dge-to-edge. she Transition From a Surgical Procedure
o the Transcatheter Approach
e firstly predicted the feasibility of a transcatheter/
ercutaneous approach adopting the edge-to-edge concept
3). Morales et al. (19) first described a device for beating-
eart edge-to-edge repair with a tissue grasper. Alfieri et al.
20) reported the early animal experience with a suture-
ased device for double orifice repair with a beating-heart,
irect transatrial approach. The device had suction ports at
ts distal tip to grasp the leaflets under echo-guidance and
ubsequently approximate them by deploying 2 single su-
ures. Then the sutures were tied with a knot pusher to get
he double orifice. In parallel, a percutaneous catheter with
imilar characteristics had been developed (21): Mobius
Edwards Lifesciences, Irvine, California). The procedure
nvolved a transeptal approach and the sequential grasping
f leaflets under echo-guidance. After needle penetration of
he leaflets, the suture was exteriorized and fastened with a
itinol suture clip to create the double orifice. The device
roved safe and effective in the animal experience. Because
uture-based approximation was closely replicating the sur-
ical predicate therapy, the device could be considered a
transcatheter needle-holder.” After the Milano II multi-
enter safety and feasibility trial, the program was discon-
inued for evidence of limited efficacy and durability. Webb
t al. (22) reported the outcomes of 15 patients treated in 4
nternational sites: acute reduction of MR was obtained in 9
f 15 patients, but improvement in MR appeared durable in
nly 6 patients at 30 days. The main limitation for the
uccess of the Mobius was lack of adequate image guidance
due to the poor echogenicity of the device). The limited
urability was related to insufficient tissue penetration of the
uture and to asymmetric deployment of sutures.
The first animal report of the MitraClip is by St. Goar et
l. (23), who reported acute procedural success in 12 of 14
nimals. Interestingly, in 2 animals the clip detached acutely
rom the anterior leaflet due to incomplete grasp. Today,
efore final release, a careful analysis of leaflet incorporation
nto the clip is carried out to prevent clip detachment. Fann
t al. (24) described the healing process in chronic animals
mplanted with the MitraClip, showing tissue incorporation
f the device similar to that observed after surgical suture
pproximation (25).
he Mitraclip:
linical Experience From
irst-in-Man to Commercial Use
he Mitraclip has been used in humans with success, due to
he very promising animal experience. The main drivers for
uccess of the therapy have been the precise and stable
elivery system, the solid and reliable tissue approximation,
he good visualization of the device, and its repositionability
nd retrievability. Although the MitraClip has been de-
igned to replicate the surgical suture-based approach, tissue
2178 Maisano et al. JACC Vol. 58, No. 21, 2011
From Surgery to Percutaneous Edge-to-Edge November 15, 2011:2174–82approximation is more efficient with better surface of
coaptation, compared with suture (Fig. 1). The main
strength of the Mitraclip is feasibility of the procedure
under beating heart conditions, guided by the regurgitant jet
position. This is particularly valuable for functional MR.
The main weakness is the limited applicability, according to
strict anatomical features, whereas surgical edge-to-edge
can be applied more widely, mainly because of annuloplasty
and combination with additional techniques.
The MitraClip delivery system includes a tri-axial cath-
eter system composed of a steerable guide catheter and a clip
delivery system catheter holding the implantable clip. The
guide catheter size is 24-F at the groin and 22-F at the atrial
septum and allows precise and stable maneuvers into the left
side of the heart. The clip is a cobalt/chromium implant
Figure 3 3D Echocardiography to Guide the MitraClip Implant P
(A) The MitraClip delivery system is positioned in the left atrium across the septu
lar to the annular plane. (B) The clip arms are opened and oriented perpendicular
is obtained. 3D  3-dimensional.including 2 arms and 2 “grippers” independently securing
the leaflets after grasping. The clip arms and grippers are
covered with polyester to enhance tissue healing.
The MitraClip is implanted through a sequence of stan-
dardized steps that have been described by the EVEREST
(Endovascular Valve Edge-to-Edge REpair Study) investi-
gators (26). The implant is performed under general anes-
thesia and guided by TEE and fluoroscopy. Transeptal
puncture is performed in the mid-superior and posterior
aspect of the fossa ovalis, to achieve proper alignment of the
system. The clip delivery system is advanced into the left
atrium, perpendicular to the annular plane (Fig. 3A). The
clip is positioned inside the MR jet, above the regurgitant
orifice, with Doppler TEE as guidance. The clip arms are
opened to 180° and oriented perpendicularly to the line of
dure
directed toward the mitral valve, along the long axis of the heart and perpendicu-
e line of coaptation. (C) The clip has been implanted, and a double orifice valveroce
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November 15, 2011:2174–82 From Surgery to Percutaneous Edge-to-Edgecoaptation (Fig. 3B). Symmetric implant is fundamental for
effective and durable repair, similarly to the surgical tech-
nique. The overall procedure today is more expeditious with
the use of 3D TEE (27), owing to both the intuitive display
of the mitral anatomy and the ability to image the device
and the target lesions in simultaneous perpendicular planes
(x-plane). The clip is advanced into the left ventricle, below
the line of coaptation, and it is partially closed to get a V
shape. Leaflets are grasped by gentle retraction of the clip
toward the left atrium. To secure the leaflets into the device,
the grippers are dropped and the clip is closed to approxi-
mately 60° to allow assessment of leaflet insertion. This step
is reversible and resembles the surgical procedure, when a
temporary central suture is used to assess symmetry and
efficacy of the position (2). When the clip is closed, the final
effect on MR reduction is evaluated, and the clip is released
(Fig. 3C). If the result is unsatisfactory, the clip can be
opened, inverted to release the leaflets and repositioned.
Alternatively a second clip can be used to improve the result
of the first one (Fig. 4). Rarely has a third clip been used in
clinical practice. At the end of the procedure, the guide
catheter is removed and the femoral access is closed. The
first-in-man procedure was performed in 2003, in a patient
with anterior leaflet prolapse. Two years after the procedure,
he patient showed mild residual MR and evidence of positive
everse remodeling (28). After the first-in-man experience, the
VEREST I feasibility study was completed in 2006, enroll-
ng 55 patients. Feldman et al. (26) reported the pooled data
from EVEREST I and 52 “roll-in” EVEREST II patients
(treated before randomization as part of the training)
demonstrating the safety of the procedure as well as efficacy
in selected patients. In the EVEREST II trial (29), a total
of 279 patients at 37 sites were randomized from September
2005 through November 2008 in a 2:1 ratio to undergo
Figure 4 Hemodynamic Outcome of a Double MitraClip Implant
(A) Bidimensional echocardiography at 60° to show the intercommissural view. Tw
(B) The diastolic flow shows no turbulence. (C) A residual minimal jet is found lateither percutaneous repair (n  184) or mitral-valve surgery(n  95). The inclusion and exclusion criteria included
restrictive clinical and anatomical variables (Table 1). The
primary efficacy composite endpoint was freedom from
death, from surgery for valve dysfunction, and from MR
three-fourths at 12 months. The primary safety endpoint
was the rate of major adverse events at 30 days, defined as
the composite of death, myocardial infarction, reoperation
for failed mitral repair, nonelective cardiovascular surgery
for adverse events, stroke, renal failure, deep wound infec-
tion, prolonged mechanical ventilation, gastrointestinal
complication requiring surgery, new-onset permanent atrial
fibrillation, septicemia, and transfusion of 2 units or more of
blood.
In the intention-to-treat analysis, the rates of death and
of recurrence of MR 3 at 12 months were similar in the
groups, whereas the rate of surgery for mitral valve
ysfunction was 20% in the Mitraclip arm, as compared
ith 2.2% in the surgery arm. Overall, the rates of the
are implanted in the middle of the valve.
o the second implanted clip.
Anatomical Selection Criteriafor the MitraClip DeviceTable 1 Anatomical S lection Criteriafor the MitraClip Device
Recommended anatomical criteria (from the EVEREST trial)
MR originates from the A2-P2 area
Coaptation length 2 mm
Coaptation depth 11 mm
Flail gap 10 mm
Flail width 15 mm
Mitral valve orifice area 4 cm2
Additional criteria for caution
Short posterior leaflet (8 mm)
Restricted posterior leaflet prolapse/flail width 15 mm
Calcification in the grasping area
Cleft or subcommissures in the area of the jeto clips
erally tMitraClip (Abbott Vascular, Menlo Park, California).
EVEREST  Endovascular Valve Edge-to-Edge REpair Study; MR  mitral regurgitation.
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From Surgery to Percutaneous Edge-to-Edge November 15, 2011:2174–82primary efficacy endpoint were 55% and 73% in the percu-
taneous and surgery group, respectively (p  0.007). In the
intention-to-treat analysis, the rates of major adverse events
at 30 days after the procedure were 15% in the MitraClip
arm and 48% in the surgery arm, with a 1-sided upper limit
of the 97.5% confidence interval of 21% (lower than the
2% margin of increased safety; p  0.001). There was
improvement in the severity of MR in the 2 groups, but it
was greater after surgery (p  0.001). In the MitraClip
roup, 23% had residual MR 2. However, the majority of
atients who had improved MR after the procedure had a
ustained improvement at 24 months of follow-up, and 78%
f patients remained free from mitral valve surgery. Despite
he difference in the reduction in MR degree, both groups
bserved a similar degree of reverse left ventricular remod-
ling and improvement of symptoms. The mismatch be-
ween MR reduction and clinical improvement raises the
ssue of the reliability of current methods of MR quantifi-
ation. Most quantitative or qualitative methods have been
esigned to assess the degree of regurgitation in the setting
f a single regurgitant orifice, whereas after the Mitraclip
ften 2 or more jets are encountered. Recently, it has been
hown that the presence of 2 regurgitant orifices results in
Figure 5 Example of an Ideal and a Suboptimal Anatomy for th
A and B are are 2 images from an ideal candidate for the MitraClip procedure. Th
C and D are 2 images from a suboptimal candidate (degenerative mitral regurgitat
whereas the 2-dimensional (2D) left ventricular outflow tract view shows a long flaoverestimation of the jet color Doppler area (30). Further-
more, the clinical meaning of a residual moderate MR
(grade 2/4) is still debated, because this outcome is
classically not acceptable after surgical repair and is
associated with accelerated repair failure. The 2-year data
suggest that recurrent MR develops in the first 6 months
after the procedure; thereafter, the hemodynamic result
of the MitraClip remains stable. Patients with failed repair
had undergone surgery with preserved repair option in the
majority of cases, although this issue is still debated (31).
post hoc analysis (non–pre-specified and purely explor-
tory) suggests that surgery was nonsuperior to the percu-
aneous treatment in patients older than 70 years and in
hose with depressed left ventricular function and functional
egurgitation.
The EVEREST II trial is debatable, both in terms of trial
esign and of results interpretation. The safety advantage of
he MitraClip is mostly driven by the higher rate of
ransfusions in the surgical arm. Unfortunately, the small
umber of patients with functional MR and the exclusive
nrollment of surgical candidates do not reflect the real-
orld patients undergoing the procedure. Currently, 2 post-
arket registries are ongoing: the ACCESS-EU in Europe,
raClip
sion of the prolapsing segment is limited (A), and the flail gap is 5 mm (B).
he 3-dimensional (3D) surgical view shows a wide prolapsing segment (C),
(D).e Mit
e exten
ion). T
il gap
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November 15, 2011:2174–82 From Surgery to Percutaneous Edge-to-Edgeand the REALISM (Real World ExpAnded MuLtIcenter
Study of the MitraClip System) in the United States. The
initial data suggest that patients undergoing the MitraClip
procedure in the real world are older, with more comorbidities,
with more depressed left ventricular function, and mostly with
functional MR. Hospital mortality remains low (below 2% in
the ACCESS-EU, despite the average logistic Euroscore at
approximately 20%), and early efficacy is improved (proce-
dural success rate 90%). Improvement of quality of life
and New York Heart Association functional class as well as
reduction of MR grade have been reported (32), but
published data are not yet available.
Patient Selection:
Surgery or Percutaneous Interventions?
Selection of the surgical versus percutaneous approach is
challenging, in the absence of evidence. In our experience,
the decision is undertaken by a heart team and individual-
ized on the basis of clinical and anatomical factors, keeping
the surgical option as first choice. High-risk patients are
considered for the procedure, but only a subgroup of
patients can be treated by the MitraClip procedure, accord-
ing to the anatomical criteria (Table 1) derived from the
EVEREST inclusion protocol. We routinely use 3D TEE
(Fig. 5) for patient screening, because it increases accuracy
and delivers a more objective assessment of the target lesions
(33). In the future, the combination of the MitraClip with
an annuloplasty device could expand indications and im-
prove efficacy and durability. Some patients treated with
anatomical characteristics beyond the EVEREST criteria
show reasonable short- and mid-term results (34,35). How-
ever, treating patients with more complex anatomy could be
associated with procedural failure and shorter durability and
should be performed only by expert operators with sufficient
experience.
In younger patients with degenerative MR without co-
morbidities, surgery can be carried out with minimal risk
and with long-lasting results (36). The Mitraclip procedure
should be considered in elderly subjects or those with
comorbidities. The ideal degenerative MR candidate has a
prolapse or flail lesion limited to 1 segment (Figs. 5A and 5B).
The width of the prolapsing segment should be 1.5 cm:
larger flails are at risk of stenosis and require multiple clips.
Technical feasibility is also influenced by the flail gap, a
measure of the distance of the free edge of the prolapsing
segment from the facing leaflet (Figs. 5C and 5D).
For functional MR, the MitraClip is emerging as a
valuable alternative, because surgical risk is usually high
(37), although the EVEREST data are missing in this field.
Compared with outcomes of degenerative patients (38),
survival benefit after surgery has not yet been demonstrated
(39), and the repair is less durable (40). Therefore, in
presence of favorable anatomical characteristics, we consider
the MitraClip as first-choice treatment, unless the patient is
a low-risk surgical candidate. However, there is a strongneed for dedicated studies in this field to clarify the clinical
role of the percutaneous treatment of functional MR versus
medical and surgical therapy or other heart failure therapies.
Conclusions
We have witnessed the evolution of a surgical procedure
into a percutaneous technique. This process is introducing
new challenges and opportunities. Minimization of inva-
siveness and intraprocedural online assessment of repair
result are the main advantages, compared with surgery. The
main challenge remains the selection of patients to be
treated with these new techniques, in the absence of strong
evidence and with still-limited clinical and technical expe-
rience. It is mandatory that the challenges are overcome by
a true teamwork effort, to enable a safe and effective
introduction of the percutaneous technologies in clinical
practice.
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